Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

Clozapine

A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month

Trial Locations (1)

30200

Tirat Carmel Mental Health Center, Tirat Carmel

All Listed Sponsors
collaborator

Technion, Israel Institute of Technology

OTHER

collaborator

Ben-Gurion University of the Negev

OTHER

collaborator

Beersheva Mental Health Center

OTHER_GOV

collaborator

Sha'ar Menashe Mental Health Center

OTHER

collaborator

HaEmek Medical Center, Israel

OTHER

collaborator

The Nazareth Hospital, Israel

OTHER

lead

Tirat Carmel Mental Health Center

OTHER_GOV

NCT01663077 - Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients | Biotech Hunter | Biotech Hunter